Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Exercise – induced changes in cerebrospinal fluid miRNAs in Gulf War Illness, Chronic Fatigue Syndrome and sedentary control subjects

An Author Correction to this article was published on 19 April 2018

This article has been updated


Gulf War Illness (GWI) and Chronic Fatigue Syndrome (CFS) have similar profiles of pain, fatigue, cognitive dysfunction and exertional exhaustion. Post-exertional malaise suggests exercise alters central nervous system functions. Lumbar punctures were performed in GWI, CFS and control subjects after (i) overnight rest (nonexercise) or (ii) submaximal bicycle exercise. Exercise induced postural tachycardia in one third of GWI subjects (Stress Test Activated Reversible Tachycardia, START). The remainder were Stress Test Originated Phantom Perception (STOPP) subjects. MicroRNAs (miRNA) in cerebrospinal fluid were amplified by quantitative PCR. Levels were equivalent between nonexercise GWI (n = 22), CFS (n = 43) and control (n = 22) groups. After exercise, START (n = 22) had significantly lower miR-22-3p than control (n = 15) and STOPP (n = 42), but higher miR-9-3p than STOPP. All post-exercise groups had significantly reduced miR-328 and miR-608 compared to nonexercise groups; these may be markers of exercise effects on the brain. Six miRNAs were significantly elevated and 12 diminished in post-exercise START, STOPP and control compared to nonexercise groups. CFS had 12 diminished miRNAs after exercise. Despite symptom overlap of CFS, GWI and other illnesses in their differential diagnosis, exercise-induced miRNA patterns in cerebrospinal fluid indicated distinct mechanisms for post-exertional malaise in CFS and START and STOPP phenotypes of GWI.


Chronic Fatigue Syndrome (CFS)1,2,3,4 and Gulf War Illness (GWI)5,6,7,8 are nociceptive, interoceptive, fatiguing illnesses that are currently defined by symptoms and exclusion of other conditions in their extensive differential diagnoses9. CFS developed from medical traditions of neurasthenia10 and viral infection11, and GWI from “signs, symptoms, and ill-defined conditions (SSID; International Classification of Diseases-9th Revision, Clinical Modification (ICD-9-CM) codes 780-799)”12. These legacies are being revised based on new discoveries about disease pathogenesis13,14,15,16,17,18. With the revisions comes an increasing need for objective biomarkers to define and diagnose these diseases.

The 1994 Center for Disease Control (CDC) criteria for CFS are: (a) moderate or severe, persistent and sustained fatigue lasting more than 6 months and causing impairment of daily activities, plus (b) moderate or severe complaints of at least 4 of 8 ancillary criteria: short term memory or problems with concentration, sore throat, sore lymph nodes, myalgia, arthralgia, sleep disturbances, new onset headaches that include migraine, and post-exertional malaise (Fig. 1)1. Post-exertional malaise, also referred to as exertional exhaustion, is an unique characteristic of CFS1,2,3,4 that is shared by GWI subjects7.

Figure 1

Overlap of diagnostic criteria for CFS1, GWI7 and major depressive disorder78. Diagnostic protocols for CFS, GWI and depression selected different sets of primary and ancillary symptoms. CFS requires fatigue, then confirmation with ≥4 of 8 ancillary criteria. Active depression and other psychiatric diseases are exclusionary diagnoses for CFS. GWI requires 3 of 7 categories of symptoms. Depression requires depressed affect and anhedonia, then sufficient supporting complaints.

Twenty six years after the First Persian Gulf War, 25% to 32% of the nearly 697,000 U.S. veterans of that conflict continue to have cognitive and physical exhaustion that is made worse by effort (exertional exhaustion), systemic pain and hyperalgesia, migraines, gastrointestinal distress with severe diarrhea, and other medical problems (Table 1)7,8. Epidemiological risk factors include exposures to low dose sarin and cyclosarin from munitions such as the demolition at Khamisiyah, Iraq; pyridostigmine bromide taken for nerve agent prophylaxis; and personal pesticides19. Objective findings that distinguish GWI subjects from their unaffected deployed and nondeployed peers and civilians include cerebrospinal fluid proteomics20, low activity butyrylcholinesterase alleles in GWI cases who used pyridostigmine (odds ratio = 40.0)21, brain white matter dysfunction with increased axial diffusivity by diffusion tensor imaging22,23, and mitochondrial dysfunction18,24. A logical hypothesis is that Gulf War era exposures to cholinesterase inhibitors19 caused acute acetylcholine neurotoxicity in persons with genetically reduced levels of acetylcholinesterase activity21, followed by chronic progression of the initial lesions18,20,22,23,24.

Table 1 Demographics and symptom severities. Mean ± SD.

We have reported that GWI veterans can be divided into two phenotypes based on responses to the physiological stressor of submaximal exercise testing25. One third of subjects developed new postural tachycardia after exercise and were positively selected as the START (Stress Test Activated Reversible Tachycardia) group. START subjects had: (i) exercise - induced postural tachycardia, (ii) increased blood oxygenation level dependent (BOLD) signal in the cerebellar vermis during a cognitive task before exercise, (iii) reduced BOLD signals during a working memory task after exercise, and (iv) reduced brainstem volumes suggesting atrophy. The remainder formed the Stress Test Originated Phantom Perception (STOPP) group because they had significantly greater BOLD activation of basal ganglia and anterior insula during cognitive testing than sedentary controls (SC) and START 25. That pattern was similar to phantom limb pain26. The two phenotypes suggest there were two mechanisms of initial injury or on-going progression that will require different diagnostic and treatment approaches.

Cerebrospinal fluid was extensively assayed for micro-RNAs (miRNA), proteomics20, metabolomics, and other analytes to interrogate the central neurotoxic pathologies proposed in GWI27 and CFS16,17. miRNAs are ~22 nucleotide long, single-stranded RNAs transcribed from genomic DNA28. They form the RNA-induced silencing complex (RISC) and bind to complementary sequences in the 3′ untranslated region of mRNAs to repress translation or promote mRNA degradation. miRNAs dynamically fine-tune the expression of most cellular proteins. Quantitative polymerase chain reaction (QPCR) was used to measure cerebrospinal fluid miRNAs.

First, we hypothesized that CFS (cfs0), GWI (gwi0) and sedentary control (sc0) subjects at rest (nonexercise, lower case italics with 0) would have significant differences in cerebrospinal fluid biomarkers from each other. The nonexercise groups rested overnight and had no exercise before their lumbar punctures. Nonexercise miRNA patterns were predicted to be different from other conditions in the differential diagnosis such as depression and fibromyalgia. Second, differences would be magnified in post-exercise SC, CFS, and the exercise-defined START and STOPP phenotypes of GWI subjects when compared to each other (upper case italics to denote post-exercise). Third, differences between the post-exercise groups and their appropriate nonexercise comparison groups (SC vs. sc0, CFS vs. cfs0, START vs. gwi0, STOPP vs. gwi0) would model the effects of exercise on the central nervous system and the pathology of exertional exhaustion.


Clinical information

All subjects gave written informed consent. The protocol was approved by the Georgetown University Institutional Review Board and the Human Research Protection Office of the Department of Defense Congressionally Directed Medical Research Program. Lumbar puncture, quantitative PCR, and other investigations were performed in accordance with currently published standards, guidelines (MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments and World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects ( The investigations were not considered clinical trials using the World Health Organization (WHO) definition (

GWI and healthy veterans, and healthy, non-military, sedentary control (SC) subjects completed questionnaires for case designation criteria of GWI (Fig. 2)7 and CFS (Fig. 3)1,29, common symptoms in CFS and GWI30, quality of life31, Generalized Anxiety Disorder 732, and Center for Epidemiologic Studies Depression Scale33 scores. Fibromyalgia was assessed by pain plus tenderness (1990 criteria)34. Clinical and methodological details were published previously25. All subjects had submaximal bicycle exercise stress tests on 2 consecutive days with magnetic resonance imaging before and afterwards, followed by a lumbar puncture25. Subjects cycled at 70% of age predicted maximum heart rate for 25 min35 followed by stepwise increases in bicycle resistance to reach 85% predicted heart rate25. Exercise was required to induce postural tachycardia that defined the START phenotype. Cerebrospinal fluid total protein, albumin and IgG were measured36 and aliquots were frozen at −80 °C until thawed for miRNA extraction.

Figure 2

Kansas Criteria for Gulf War Illness scoring form based on Steele7. ©JNBaraniukMD_17g13. Used with permission of the copyright holder.

Figure 3

Chronic Fatigue Syndrome Symptom Severity Questionnaire. ©JNBaraniukMD_17g13 Used with permission of the copyright holder.

Quantitative PCR

miRNA analysis was completed in blinded fashion by N.S. without knowledge of subject diagnosis. Total RNA was isolated by mixing 0.5 ml cerebrospinal fluid 1:10 with QIAzol™ lysis reagent (Qiagen) and 0.1 ml CHCl3 before vortexing for 1 min37,38,39. miRNA was extracted from the upper phase using miRNAeasy Mini Kits (Qiagen). miRNA levels were estimated by optical density of cDNA after reverse transcription with miScriptII RT kits (Qiagen). miRNA expression profiling used miScript PCR arrays for 380 miRNAs and miScript SYBRgreen PCR kits (Qiagen) on an ABI 7900 HT Real-Time PCR system (Applied Biosystems) and manufacturer’s protocol.

miRNA selection

The first level of constraint required miRNAs to be detectable with PCR cycle threshold (Ct) ≤ 35. miRNAs with Ct > 35 were designated as “undetectable” and 35 was imputed as their Ct. Second, in order to be considered a viable biomarker, miRNA had to detectable with Ct ≤ 35 in at least two thirds of subjects in a group.

miRNA normalization and ΔΔCt

Four normalization strategies and ΔΔCt computations were compared.

The N0 (no normalizer) analysis used the entire dataset with 35 imputed for all Ct > 35. The average ΔCt was calculated for each group, then ΔΔCt determined between each pair of groups40. Significantly different miRNAs were detected by one-way ANOVA followed by Tukey’s Honest Significant Difference (HSD; p < 0.05). Student’s 2-tailed unpaired t-tests were computed for all miRNAs and pairs of groups, and False Discovery Rates (FDR) calculated to correct for multiple comparisons41. FDR ≤ 0.10 was used as the next constraint to detect significant differences in ΔΔCt. The other normalizers used 2 (N2), 3 (N3) and 6 (N6) miRNAs. For each individual, ΔCt was calculated as the difference of the N2, N3 or N6 normalizer minus the Ct for each of the other miRNAs. Average ΔCt and ΔΔCt were calculated.

Outcomes were: (i) differences between non-exercise groups (sc0, cfs0 and gwi0), (ii) differences between groups after exercise (SC, START, STOPP, CFS), and (iii) exercise–induced differences between each post-exercise group and its appropriate non-exercise control group. ΔΔCt data were reported as mean ± SD to allow calculation of Cohen’s d (mean difference/SDpooled) and to predict future sample sizes42. Receiver operating characteristics were calculated for each significant ΔΔCt in SPSS 24.



CFS groups (cfs0, CFS) had more females, and GWI groups (gwi0, START, STOPP) more males (Table 2). Quality of life31, fatigue, cognitive, sleep, pain and interoceptive symptoms29,30 were significantly impaired in GWI and CFS groups compared to sedentary control subjects. Fibromyalgia (1990 criteria) was more prevalent in CFS and GWI than controls34. The case designation criteria of GWI, CFS, generalized anxiety and depression share fatigue, sleep, cognition, and sympathetic nervous system symptoms32. The Center for Epidemiology – Depression questionnaire found depression in 78.3% of GWI, 64.0% of CFS and 25.0% of control subjects33. Generalized Anxiety Disorder 7 scores were significantly higher for gwi0 and START compared to sc0 (FDR < 0.01) and SC (FDR < 0.01), respectively33. Cerebrospinal fluid total protein, albumin, IgG and their ratios were equivalent between groups36.

Table 2 Receiver operating characteristics.


The raw data were placed in Supplementary Table S1. The statistical constraints reduced the number of miRNAs that were candidates for biomarkers and normalizers down to 88 (Supplementary Table S2).

Supplementary Tableas the raw Ct data with 35 imputed for all Ct > 35 (Supplementary Table S3).

The N2 normalizer used miR-489 and miR-490-3p because they (i) were detected in all subjects with Ct ≤ 35, (ii) were abundant in cerebrospinal fluid, (iii) had small variances (25.2 ± 0.8 and 25.5 ± 0.9, respectively, mean ± SD) with narrow ranges for Ct (minimum 22.8 to maximum 27.8, and minimum 22.3 to maximum 28.1, respectively), and (iv) were not significantly different between groups (ANOVA > 0.05 and FDR > 0.10 for each pairing) (Fig. 4).

Figure 4

Normalizer miRNAs. Data are shown as Ct for each miRNA (N0 normalizer). The N2 normalizer used (a) miR-489 and (b) miR-490-3p. N3 added (c) miR-127-3p. The N6 normalizer added (d) miR-433, (e) miR-124-3p, and (f) miR-183-3p. Each miRNA had ΔΔCt < 1.0 between groups, ANOVA > 0.05, FDR > 0.10, and were detectable in at least 180 of the 182 subjects. The blue line indicates Ct = 35. Nonexercise groups were control (sc0, grey circles), Chronic Fatigue Syndrome (cfs0, grey triangles), and Gulf War Illness (gwi0, grey diamonds). Post-exercise groups were control (SC, yellow circles), Chronic Fatigue Syndrome (CFS, blue triangles), and the Gulf War Illness START (green squares) and STOPP (red diamonds) phenotypes. Mean ± SD.

The N3 normalizer was the mean of miR-489, miR-490-3p and miR-127-3p (29.3 ± 1.2, mean ± SD, minimum 24.2, maximum 35). Two Ct values were 35; the averages for the 2 groups were imputed instead of 35 for this normalizer (26.6 ± 2.1, mean ± SD).

The N6 normalizer added miR-124-3p (30.6 ± 1.7, mean ± SD), miR-183-3p (31.8 ± 1.0, mean ± SD), and miR-433 (29.9 ± 1.5, mean ± SD). Two subjects each had 35 imputed for miR-127-3p, miR-183-3p and miR-433; the N6 normalizer included these values (28.7 ± 2.8, mean ± SD). Ct data for these 6 miRNAs were shown in Fig. 4.

All normalizer miRNAs had ΔΔCt < 1.0, ANOVA > 0.05, FDR > 0.10 and were detectable in at least 180 of the 182 subjects (Supplementary Table S2).

The N0 normalizer selected 31 miRNAs that met the significance criteria of (i) being detected with Ct ≤ 35 in more than two thirds of subjects in at least 1 of the 7 groups, (ii) HSD ≤ 0.05, and (iii) FDR ≤ 0.10. N2 identified 21, N3 had 24, and N6 found 23 significant miRNAs. The intersection of the 4 normalizers identified 18 miRNAs with at least 1 significant difference between groups (Fig. 5). One was added by the intersection of 3 normalizers. There was excellent agreement for the magnitudes of ΔΔCt between the 4 normalizers (Supplementary Tables S4 and S5). In contrast, N0 selected 9 additional miRNAs that were not found with N2, N3 and N6 (Fig. 5). These were considered false positive results.

Figure 5

Intersection of miRNAs from each normalizer. The intersection of N0, N2, N3, and N6 identified 16 miRNAs that had at least 1 significant difference between groups (central yellow boxes). N0, N2 and N6 and N2, N3 and N6 added one each. Pairs of normalizers identified 6 miRNAs that were not considered significant. N0 was least selective as it identified an additional 12 miRNAs that were considered false positives. Therefore, the miRNAs selected by 3 or 4 normalizers were the set of significantly different miRNAs.

Nonexercise groups

None of the miRNAs were significantly different between nonexercise groups using our stringent criteria. miR-22-3p ΔCt values were higher in cfs0 than sc0, but the differences were not significant after ANOVA and Tukey tests.

Post-exercise groups

miR-22-3p and miR-9-3p were the only miRNAs to be significantly different between the post-exercise groups (Fig. 6). miR-22-3p was an anomaly by having wide ranges of Ct in all groups. miR-22-3p was virtually not detectable in START, and so levels in START were significantly diminished compared to SC and STOPP (Supplementary Table S6). The reduction in START, but relative increase in STOPP, supported the presence of 2 phenotypes of GWI. Specificities and sensitivities were 0.76 for START versus SC (Ct threshold of 29) and START versus STOPP (Ct threshold of 33) (Table 2).

Figure 6

miRNA differences between post-exercise groups. (a) miR-22-3p was not detectable in most of the START subjects (green squares above the blue line at Ct = 35). START had significantly less miR-22-3p than SC (yellow circles) and STOPP (red diamonds) as indicated by bars over top of the groups (HSD < 0.05, FDR < 0.10). In addition, SC had significantly more miR-22-3p than sc0 (grey circles). (b) miR-9-3p was detected in START, but was found in fewer than two thirds of subjects in the other groups. START had significantly more miRNA expression than STOPP (ΔΔCt = 1.6 ± 1.4, mean ± SD, HSD < 0.05, FDR < 0.10).

miR-9-3p demonstrated a different trend. Only the START group had detectable levels (Ct ≤ 35) in more than two thirds of subjects. The difference between START and STOPP was small (Fig. 6, Supplementary Table S6) but significant (HSD < 0.05, FDR < 0.05). The low specificity and sensitivity of 65% at a threshold of Ct = 33 reflected the low levels of miR-9-3p in cerebrospinal fluid.

miRNAs elevated after exercise compared to nonexercise groups

Exercise elevated the levels of several miRNAs compared to appropriate nonexercise groups. SC had higher levels than sc0 for miR-22-3p (Fig. 6), miR-30d-5p, miR-204-5p, miR-425-3p, and miR-99b-5p (Fig. 7). Specificities and sensitivities for miR-204-5p and miR-22-3p were 0.80 at thresholds of 31 and 32, respectively.

Figure 7

miRNAs that were significantly elevated in post-exercise compared to appropriate nonexercise control groups. Significant differences between groups were indicated by the bars at the top of the graphs for (a) miR-99b-5p, (b) miR-425-3p, (c) miR-30d-5p, (d) miR-204-5p, and (e) miR-370 (HSD ≤ 0.05, FDR ≤ 0.10, detected with Ct ≤ 35 in more than two thirds of one group per pair). The horizontal blue line indicated Ct = 35. Mean ± SD.

START had elevated levels of miR-425-3p and miR-99b-5p when compared to gwi0. miR-370 was detected in almost all cerebrospinal fluid samples, but only START had a significant elevation compared to nonexercise (ΔΔCt = 1.7 ± 2.1 versus gwi0, mean ± SD). STOPP shared the exercise – induced elevation of miR-99-5p with SC and START. Specificities and sensitivities for miR-99b-5p were about 0.75 at Ct thresholds of 33 for SC, START and STOPP compared to their nonexercise controls.

CFS did not have any elevations of miRNA levels compared to cfs0.

miRNAs diminished after exercise compared to nonexercise groups

miR-328 and miR-608 were significantly diminished by exercise in SC, CFS, START and STOPP compared to the nonexercise sc0, cfs0, and gwi0 groups (Fig. 8). These miRNAs were detectable in almost all cerebrospinal fluid specimens in this study. Specificities and sensitivities for miR-328 ranged from 0.74 at Ct = 23 for SC, 0.84 for CFS, 0.86 for STOPP and 0.91 for START (Ct thresholds of 23 to 25). Specificities and sensitivities for miR-608 ranged from 0.78 to 0.83 (thresholds = 28). Diminished miR-328 and miR-608 may be a consequence of exercise that affected all subjects regardless of their disease status.

Figure 8

Decreased (a) miR-328 and (b) miR-608 levels in SC, CFS, START and STOPP groups after exercise.

miR-let-7i-5p, miR-200a-5p and miR-93-3p were significantly reduced in START, STOPP and CFS compared to their gwi0 and cfs0 nonexercise controls (Fig. 9). They were unchanged between SC and sc0 groups.

Figure 9

miRNAs reduced by exercise. GWI phenotypes (START and STOPP) and CFS all had reductions in (a) miR-let-7i-5p, (b) miR-200a-5p and (c) miR-93-3p. Sedentary controls had no changes.

CFS was distinguished from the other groups by having significant reductions of miR-126-5p, miR-186-3p, miR-19b-3p, miR-92a-3p and miR-505-3p compared to the nonexercise cfs0 group (Fig. 10). Specificities and sensitivities were about 0.82 for miR-328, miR-608 and miR-92a-3p. The large number of exercise – induced reductions in miRNAs differentiated CFS from SC and the GWI phenotypes.

Figure 10

Decreased miRNAs after exercise in CFS group. CFS had significant reductions in -(a) 92a-3p, (b) miR-323b-5p, (c) miR-126-5p, (d) miR-19b-3p, (e) miR-505-3p, (f) miR-532-5p, and (g) miR-186-3p, compared to its nonexercise cfs0 comparison group (bars above the groups).


Cerebrospinal fluid miRNA levels for females and males in the nonexercise and the post-exercise groups were equivalent except for a significantly higher level of miR-9-3p in START than STOPP males (ΔΔCt = 1.7 ± 1.4)43.

The only exercise - induced change in females was a reduction in miR-328 in the STOPP group compared to gwi0 (5.7 ± 0.8). Samples sizes for the post-exercise SC and START females (n = 3 each) were too small to infer meaningful differences.

The post-exercise control males had significantly elevated miR-204-3p (4.4 ± 2.8), miR-30d-5p (3.4 ± 2.3) and miR-30a-5p (2.9 ± 2.0) compared to nonexercise males.

miR-328 was reduced by exercise in START (7.2 ± 5.4), STOPP (6.9 ± 4.8) and CFS (5.7 ± 3.7) males compared to nonexercise males. Control males had a similar magnitude change that was not significant by FDR (3.3 ± 3.2). STOPP males had significantly diminished miR-608 (4.6 ± 3.2) and miR-200a-5p (3.7 ± 2.1).

These differences were consistent with the overall group effects


This is the first description of the effects of exercise on cerebrospinal fluid miRNA expression in healthy subjects. Exercise diminished miR-328 and miR-608 in all subjects suggesting a general effect on the brain (Fig. 8, Supplementary Table S5). Exercise caused distinct patterns of miRNA changes in CFS and the START and STOPP phenotypes of GWI indicating significant pathophysiological differences between conditions.

Unlike our starting hypothesis, there were no differences in miRNA levels between the nonexercise groups of control, CFS and GWI subjects. Therefore, baseline levels of cerebrospinal fluid miRNAs may not be useful for diagnosis of CFS or GWI.

The only significant differences between groups after exercise were diminished miR-22-3p in START compared to SC and STOPP, and elevated miR-9-3p in START compared to STOPP (Fig. 6). These differences between START and STOPP support our 2 phenotypes of GWI25.

The most striking findings were the changes between post-exercise groups and their appropriate nonexercise comparison groups. SC had 5 elevated miRNAs after exercise, compared to 3 for START, 1 for STOPP, and none in CFS (Fig. 7, Supplementary Table S4).

The reduction of miR-608 after exercise has implications for the cholinergic hypothesis of GWI pathophysiology because it targets acetylcholinesterase and interleukin-6 (IL6) mRNAs. miR-608 binds weakly to the single-nucleotide polymorphism rs17228616 allele in the 3′-untranslated region of acetylcholinesterase mRNA44. Homozygotes for rs17228616 have reduced affinity for miR-608. This promotes mRNA stability and increases acetylcholinesterase protein translation. As a consequence, more miR-608 is available to bind to IL6 mRNA and reduces its translation. This allele also contributes to reduced cortisol and elevated blood pressure. Because rs17228616 promotes higher acetylcholinestase activity, it may be relatively protective against nerve agent and pyridostimine bromide exposure.

miR-let-7i-5p, miR-93-3p and miR-200a-5p were significantly diminished after exercise in START, STOPP and CFS, but not SC (Fig. 9). This was consistent with a cardinal finding in CFS and GWI: function may appear normal when rested, but will deteriorate after a physiological stressor1,2,3,4,7,25,45,46. miR-let-7i was reduced in plasma after exercise in athletes47. miR-let-7i has decreased expression in the prefrontal cortex of FSL rats in a model of depression48. IL6 is a target of miR-let-7i, and, as predicted, this cytokine was significantly elevated in the brains of these rats. When FSL rats were given access to running wheels, their miR-let-7i expression was increased and IL6 reduced. Modulation of miR-let-7i and IL-6 may contribute to exercise-induced benefits in “inflammatory” depression48. miR-let-7i also contributes to the regulation of acetylcholine’s muscarinic and α4β2 nicotinic receptors and epigenetic regulation of acetylcholinesterase. These animal models may not be appropriate for CFS or GWI because human subjects develop exertional exhaustion after exercise, and are unlikely to significantly increase spontaneous exercise levels when provided with a treadmill45.

The CFS group had 12 miRNAs reduced after exercise. miR-186-3p was decreased in aging mice49 where it targets β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) mRNA. Diminished miR-186-3p allows increased BACE1 mRNA translation and cleavage of amyloid peptides that increase the risk for brain disease. miR-19b-3p was reduced in serum from Alzheimer’s patients, and targeted signal transduction and activator of transcription 3 (STAT3) mRNA in a murine model50. miR-92a-3p was increased in glioblastoma and targeted BCL2L11 to reduce tumor apoptosis51. Its reduction after exercise may promote apoptosis in CFS. miR-126-5p was highly expressed in endothelial cells where it targets vascular (VCAM), intercellular (ICAM) and activated leukocyte (ALCAM) cell adhesion molecule mRNAs and so reduces transendothelial migration52,53. This is relevant for immune cell influx into the brain, and hypotheses of neuroinflammation in CFS pathogenesis.

Neurons may be the sources of miR-124-3p, miR-127-3p, miR-433, and miR-323b-5p (Figs 4 and 10)54. There was little overlap with the miRNAs synthesized in astrocytes, oligodendrocytes and microglia.

The choroid plexus epithelium may be a primary source of miRNAs in cerebrospinal fluid55,56,57. Epithelial cells form a monolayer linked by tight junctions that creates the “shrink wrapped” cellular barrier around fenestrated capillaries58. Interferon-gamma and other mediators generated by exercise, inflammation, and other stressors act directly on choroid plexus to modulate barrier permeability, plasma protein transport, protein synthesis and secretion of nutrients into cerebrospinal fluid59,60,61. miR-328, which was present in all subjects and reduced after exercise (Fig. 8), binds to the 3′-untranslated regions of CD44 and collagen type 1α1 mRNAs to modulate extracellular barrier functions62. Choroid plexus miRNAs55 are packaged into extracellular vesicles and released into cerebrospinal fluid56,57,63,64. Downstream targets include subventricular neural stem cells, mature neurons, astrocytes, oligodendrocytes, microglia, meningeal and central immune cells56,57,63,65,66,67. Blockade of extracellular vesicle secretion from choroid plexus cells decreased brain inflammation in a mouse model of lipopolysaccharide-induced inflammation56. Choroid plexus miRNAs may be novel drug targets to modulate acute illness behaviours, fever, and chronic pain in systemic illnesses.

Choroid plexus is dysfunctional in Alzheimer’s disease68. This provides the rationale to consider the role of the blood – cerebrospinal fluid barrier in the cognitive dysfunction of CFS and GWI. There are numerous reports of elevated and diminished miRNAs in cerebrospinal fluid in Alzheimer’s disease36,69,70,71,72,73,74, but none matched the patterns of our groups. miR-let-7i-5p36 was elevated in Alzheimer’s, but levels were equivalent in nonexercise groups (Fig. 8).

Depression is in the differential diagnosis because of the shared ancillary diagnostic criteria (Fig. 1)75,76,77,78. Major depressive disorder is defined by affective dysfunction with sadness, flat affect and anhedonia as essential features, followed by secondary criteria including fatigue, cognitive, sleep, and somatic dysfunction78. However, screening questionnaires for depression emphasize somatic symptoms79,80. Complaints of fatigue, sleep, and cognitive dysfunction will inflate total questionnaire scores, and may lead to false positive inference of major depressive disorder even if anhedonia or affective complaints are absent81,82,83. This is particularly problematic in CFS and GWI where these features are diagnostic criteria (Fig. 1). As a result, Center for Epidemiology – Depression (CESD)33 scores were significantly elevated in GWI (78.3%), CFS (64.0%) and control (25.0%) groups (Table 1).

Quantitative PCR of miRNAs offers a more objective solution84. miR-16 in cerebrospinal fluid was significantly lower in major depressive disorder patients than control subjects85. However, this was not confirmed in an independent group who had a different pattern of 11 significantly elevated and 5 reduced miRNAs86. Our data did not confirm either of these findings because only 3 of the miRNAs were detected with Ct ≤ 35 in more than two thirds of our nonexercise group. miR-425-3p was significantly reduced in depression patients84,85,86, and was detected in about half of all nonexercise subjects. It was increased after exercise in SC, START and STOPP but not CFS (Fig. 7). This lack of reproducibility highlights the need to independently verify miRNA findings, and supports our rationale for strict statistical criteria to define potential miRNA biomarkers.

The pain and tenderness of GWI subjects (Table 1) indicated systemic hyperalgesia and suggested parallels with fibromyalgia34. Nine miRNAs were virtually undetectable in 10 fibromyalgia women compared to 8 healthy control women87. miR-99b-5p and miR-29a-3p were absent in fibromyalgia, but were detected in more than two thirds of our participants. miR-99b-5p was significantly increased after exercise in SC, START and STOPP (Fig. 7). The other 7 miRNAs were detected in less than half of our specimens. This suggested that GWI and CFS were distinct from fibromyalgia.

Limitations to the diagnostic use of quantitative miRNA analysis in cerebrospinal fluid include the remarkable lack of consensus about miRNA levels in control subjects. This can be remedied by standardization of reagents and protocols72, open source sharing of study outcomes, and meta-analysis of the raw data. The yield of extracted miRNA88 and detectability were improved with 0.5 ml instead of 0.2 ml of cerebrospinal fluid36,87. QPCR with Ct cut-offs ≤ 35 cycles reduced amplification artifacts73,87. The wide range of miR-22-3p Ct values (Fig. 6) may be due to commercial changes in reagents designed to improve miRNA detection. Highly abundant miRNAs that were detected with Ct < 35 in all subjects were used as normalizers (Fig. 4) rather than the global average level, miR-423-5p, miR-124-3p or U636,71,73,86,89. Constraints included (i) significant ANOVA and Tukey HSD between groups, (ii) significant FDR to correct for multiple comparisons, and (iii) focusing on miRNAs that were detected in more than two thirds of subjects per group that may be viable biomarker candidates for use in the general population36,71,86. Ages were comparable between groups74 (Table 1) and there were no differences in expression between males and females43,87. Next generation sequencing is an excellent discovery tool but needs careful internal standardization to be as sensitive as QPCR for quantification90,91,92. Adequate sample sizes were essential because our initial findings with about a dozen subjects per group showed differences between START and STOPP after exercise93, but these differences eventually regressed to the mean as more subjects were analyzed. This is especially pertinent to smaller studies examining the differential diagnosis of CFS and GWI85,86,87,94,95.

Limitations of the testing paradigm include the intensive nature of the exercise and magnetic resonance imaging characterization of GWI subjects to determine their phenotypes. Lumbar puncture was required to obtain the cerebrospinal fluid miRNA biomarkers, but this procedure is not a contraindication to making an objective diagnosis of GWI. On the contrary, magnetic resonance imaging with cerebrospinal fluid QPCR miRNA profiling may be complementary tools for diagnosis of CFS, GWI and their subtypes.


Cerebrospinal fluid miRNA levels were equivalent between SC, CFS and GWI subjects who had rested before exercise (nonexercise groups). miRNA levels were different from the ones that are altered in depression, fibromyalgia, and Alzheimer’s disease suggesting that these are all distinct diseases, or that the data from those smaller studies could not be replicated in this larger study. miRNA levels were equivalent between the post-exercise SC, CFS and GWI phenotypes of START and STOPP with the exception of miR-22-3p and miR-9-3p that significantly distinguished START from STOPP. This adds another layer of evidence to support neurotoxic pathology in GWI27 and these 2 phenotypes of GWI veterans25. Post-exercise levels were significantly elevated (n = 6) or diminished (n = 12) compared to the nonexercise comparison groups. miR-328 and miR-608 were elevated in SC, CFS, START and STOPP and may be a global marker of the exercise stressor on the choroid plexus and brain. CFS had 12 diminished and zero elevated miRNAs after exercise indicating its pathophysiology and responses to exercise were unique compared to GWI and control subjects. Despite the symptom overlap of CFS, GWI and other illnesses in the differential diagnosis (Fig. 1), the distinct exercise-induced miRNA patterns in cerebrospinal fluid imply separate mechanisms for post-exertional malaise in these diseases.

Change history

  • 19 April 2018

    A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.


  1. 1.

    Fukuda, K. et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 121, 953–9 (1994).

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Carruthers, B. M. et al. Myalgic Encephalomyelitis/chronic fatigue syndrome: Clinical working case definition, diagnostic and treatments protocols. J. C. F. S. 11, 7–115 (2003).

    Google Scholar 

  3. 3.

    Carruthers, B. M. et al. Myalgic Encephalomyelitis: International Consensus Criteria. J. Intern. Med. (2011).

    PubMed  PubMed Central  Google Scholar 

  4. 4.

    Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. (Institute of Medicine, 2015).

  5. 5.

    Centers for Disease Control and Prevention (CDC). Unexplained illness among Persian Gulf War veterans in an Air National Guard Unit: preliminary report–August 1990-March 1995. M.M.W.R. Morb. Mortal. Wkly. Rep. 44, 443–7 (1995).

  6. 6.

    Fukuda, K. et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. J.A.M.A. 280, 981–8 (1998).

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Steele, L. Prevalence and patterns of Gulf War illness in Kansas veterans: association of symptoms with characteristics of person, place, and time of military service. Am. J. Epidemiol. 152, 992–1002 (2000).

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Gulf War Illness and the Health of Gulf War Veterans, 57 29–30 (Research Advisory Committee on Gulf War Veterans’ Illnesses, 2008).

  9. 9. Accessed January 2, 2017.

  10. 10.

    Greenberg, D. B. Neurasthenia in the 1980s: chronic mononucleosis, chronic fatigue syndrome, and anxiety and depressive disorders. Psychosomatics. 31, 129–37 (1990).

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Holmes, G. P. et al. A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause? J.A.M.A. 257, 2297–302 (1987).

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Roy, M. J., Koslowe, P. A., Kroenke, K. & Magruder, C. Signs, symptoms, and ill-defined conditions in Persian Gulf War veterans: findings from the Comprehensive Clinical Evaluation Program. Psychosom. Med. 60, 663–8 (1998).

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Naviaux, R. K. et al. Metabolic features of chronic fatigue syndrome. Proc. Natl. Acad. Sci. USA 113, E5472–80 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. 14.

    Fluge, Ø. et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. J.C.I. Insight. 1, e89376 (2016).

    Google Scholar 

  15. 15.

    Barnden, L. R. et al. Evidence in chronic fatigue syndrome for severity-dependent upregulation of prefrontal myelination that is independent of anxiety and depression. N.M.R. Biomed. 28, 404–13 (2015).

    Google Scholar 

  16. 16.

    Barnden, L. R. et al. Autonomic correlations with MRI are abnormal in the brainstem vasomotor centre in Chronic Fatigue Syndrome. Neuroimage Clin. 11, 530–7 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Iacob, E. et al. Gene Expression Factor Analysis to Differentiate Pathways Linked to Fibromyalgia, Chronic Fatigue Syndrome, and Depression in a Diverse Patient Sample. Arthritis Care Res. (Hoboken). 68, 132–40 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Abdullah, L. et al. Translational potential of long-term decreases in mitochondrial lipids in a mouse model of Gulf War Illness. Toxicology 372, 22–33 (2016).

    CAS  Article  PubMed  Google Scholar 

  19. 19.

    Steele, L. et al. Complex factors in the etiology of Gulf War illness: wartime exposures and risk factors in veteran subgroups. Environ. Health Perspect. 120, 112–118 (2012).

    Article  PubMed  Google Scholar 

  20. 20.

    Baraniuk, J. N. et al. A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid. BMC Neurol. 5, 22 (2005).

    Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Steele, L. et al. Butyrylcholinesterase genotype and enzyme activity in relation to Gulf War illness: preliminary evidence of gene-exposure interaction from a case-control study of 1991 Gulf War veterans. Environ. Health 14, 4 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Rayhan, R. U. et al. Increased brain white matter axial diffusivity associated with fatigue, pain and hyperalgesia in Gulf War illness. PLoS One 8, e58493 (2013).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Chao, L. L. et al. Effects of low-level sarin and cyclosarin exposure and Gulf War Illness on brain structure and function: a study at 4T. Neurotoxicology 32, 814–22 (2011).

    CAS  Article  PubMed  Google Scholar 

  24. 24.

    Koslik, H. J., Hamilton, G. & Golomb, B. A. Mitochondrial dysfunction in Gulf War illness revealed by 31Phosphorus Magnetic Resonance Spectroscopy: a case-control study. PLoS One. 9, e92887 (2014).

    ADS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Rayhan, R. U. et al. Exercise challenge in Gulf War Illness reveals two subgroups with altered brain structure and function. PLoS One 8, e63903 (2013).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  26. 26.

    Liaw, M. Y. et al. Central representation of phantom limb phenomenon in amputees studied with single photon emission computerized tomography. Am. J. Phys. Med. Rehabil. 77, 368–75 (1998).

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    White, R. F. et al. Recent research on Gulf War illness and other health problems in veterans of the 1991 Gulf War: Effects of toxicant exposures during deployment. Cortex. 74, 449–75 (2016).

    Article  PubMed  Google Scholar 

  28. 28.

    Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597–610 (2010).

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Baraniuk, J. N. et al. A Chronic Fatigue Syndrome (CFS) severity score based on case designation criteria. Am. J. Transl. Res. 5, 53–68 (2013).

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Baraniuk, J. N., Clauw, D. J. & Gaumond, E. Rhinitis symptoms in chronic fatigue syndrome. Ann. Allergy Asthma Immunol. 81, 359–65 (1998).

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Ware, J. E. Jr. & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care. 30, 473–83 (1992).

    Article  PubMed  Google Scholar 

  32. 32.

    Löwe, B. et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med. Care. 46, 266–274 (2008).

    Article  PubMed  Google Scholar 

  33. 33.

    Roberts, R. E. & Vernon, S. W. The Center for Epidemiologic Studies Depression Scale: its use in a community sample. Am. J. Psychiatry 140, 41–6 (1983).

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Wolfe, F. et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 33, 160–72 (1990).

    CAS  Article  PubMed  Google Scholar 

  35. 35.

    Light, A. R. et al. Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. J. Intern. Med. 271, 64–81 (2012).

    CAS  Article  PubMed  Google Scholar 

  36. 36.

    Sørensen, S. S., Nygaard, A. B. & Christensen, T. miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia - an exploratory study. Transl. Neurodegener. 5, 6 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Shivapurkar, N. et al. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. PLoS One. 9, e84686 (2014).

    ADS  Article  PubMed  PubMed Central  Google Scholar 

  38. 38.

    LaConti., J. J. et al. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One 6, e20687 (2011).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Shivapurkar, N. et al. Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. Int. J. Colorectal Dis. 28, 887 (2014).

    Article  Google Scholar 

  40. 40.

    Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the Delta Delta C(t) method. Methods. 25, 402–8 (2001).

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. J. Royal Stat. Soc. B (Methodological). 57, 289–300 (1995).

    MATH  Google Scholar 

  42. 42.

    Cohen, J. Statistical power analysis for the behavioral sciences. (2nd ed.). (Lawrence Earlbaum Associates. 1988).

  43. 43.

    Smylie, A. L. et al. A comparison of sex-specific immune signatures in Gulf War illness and chronic fatigue syndrome. BMC Immunol. 14, 29 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Hanin, G. Competing targets of microRNA-608 affect anxiety and hypertension. Human Molecular Genetics. 1, 12, (2014).

    Google Scholar 

  45. 45.

    Keller, B. A., Pryor, J. L. & Giloteaux, L. Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO2peak indicates functional impairment. J. Transl. Med. 12, 104 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  46. 46.

    Rayhan, R. U. et al. Prefrontal lactate predicts exercise-induced cognitive dysfunction in Gulf War Illness. Am. J. Transl. Res. 5, 212–23 (2013).

    PubMed  PubMed Central  Google Scholar 

  47. 47.

    Nielsen, S. et al. The miRNA plasma signature in response to acute aerobic exercise and endurance training. PLoS One 9, e87308 (2014).

    ADS  Article  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Wei, Y. B. et al. Elevation of Il6 is associated with disturbed let-7 biogenesis in a genetic model of depression. Transl Psychiatry. 6, e869 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Kim, J. et al. miR-186 is decreased in aged brain and suppresses BACE1 expression. J. Neurochem. 137, 436–45 (2016).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Wu, Y. et al. Lower Serum Levels of miR-29c-3p and miR-19b-3p as Biomarkers for Alzheimer’s Disease. Tohoku J. Exp. Med. 242, 129–136 (2017).

    Article  PubMed  Google Scholar 

  51. 51.

    Niu, H. et al. miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. Oncol. Rep. 28, 1771–7 (2012).

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Cayrol, R. et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 9, 137–45 (2008).

    CAS  Article  PubMed  Google Scholar 

  53. 53.

    Harris, T. A. et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. USA 105, 516–1521 (2008).

    Article  Google Scholar 

  54. 54.

    Jovičić., A. et al. Comprehensive expression analyses of neural cell-type- specific miRNAs identify new determinants of the specification and maintenance of neuronal phenotypes. J. Neurosci. 33, 5127–37 (2013).

    Article  PubMed  Google Scholar 

  55. 55.

    Deo, M., Yu, J. Y., Chung, K. H., Tippens, M. & Turner, D. L. Detection of mammalian microRNA expression by in situ hybridization with RNA oligonucleotides. Dev. Dyn. 235, 2538–2548 (2006).

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Balusu, S. et al. Identification of a novel mechanism of blood-brain communication during peripheral inflammation via choroid plexus-derived extracellular vesicles. E.M.B.O. Mol. Med. 8, 1162–83 (2016).

    CAS  Article  Google Scholar 

  57. 57.

    Falcão, A. M. et al. The path from the choroid plexus to the subventricular zone: go with the flow! Front. Cell. Neurosci. 6, 34 (2012).

    MathSciNet  Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Keep, R. F. & Jones, H. C. A morphometric study on the development of the lateral ventricle choroid plexus, choroid plexus capillaries and ventricular ependyma in the rat. Brain Res. Dev. Brain. Res. 56, 47–53 (1990).

    CAS  Article  PubMed  Google Scholar 

  59. 59.

    Nilsson, C., Lindvall-Axelsson, M. & Owman, C. Neuroendocrine regulatory mechanisms in the choroid plexus-cerebrospinal fluid system. Brain Res. Brain Res. Rev. 17, 109–38 (1992).

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Marques, F. et al. The choroid plexus response to a repeated peripheral inflammatory stimulus. BMC Neurosci. 10, 135 (2009).

    Article  PubMed  PubMed Central  Google Scholar 

  61. 61.

    Marques, F. et al. Kinetic profile of the transcriptome changes induced in the choroid plexus by peripheral inflammation. J. Cereb. Blood Flow Metab. 29, 921–32 (2009).

    CAS  Article  PubMed  Google Scholar 

  62. 62.

    Rutnam, Z. J. & Yang, B. B. The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functions. J. Cell Sci. 125, 2075–85 (2012).

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Bátiz, L. F. et al. Exosomes as novel regulators of adult neurogenic niches. Front. Cell Neurosci. 9, 501 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  64. 64.

    Akers, J. C. et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neurooncol. 123, 205–16 (2015).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Doetsch, F. et al. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97, 703–716 (1999).

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Fuentealba, L. C., Obernier, K. & Alvarez-Buylla, A. Adult neural stem cells bridge their niche. Cell. Stem Cell. 10, 698–708 (2012).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Baruch, K. & Schwartz, M. CNS-specific T cells shape brain function via the choroid plexus. Brain Behav. Immun. 34, 11–6 (2013).

    CAS  Article  PubMed  Google Scholar 

  68. 68.

    Bergen, A. A. et al. Gene expression and functional annotation of human choroid plexus epithelium failure in Alzheimer’s disease. BMC Genomics. 16, 956 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Alexandrov, P. N. et al. microRNA (miRNA) speciation in Alzheimer’s disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol. 3, 365–73 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  70. 70.

    Dangla-Valls, A. et al. CSF microRNA profiling in Alzheimer’s Disease: a screening and validation study. Mol. Neurobiol. 2016 Oct 13. [Epub ahead of print].

  71. 71.

    Kiko, T. et al. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer’s disease. J. Alzheimers Dis. 39, 253–9 (2014).

    CAS  PubMed  Google Scholar 

  72. 72.

    Müller, M. et al. MicroRNA-29a is a candidate biomarker for Alzheimer’s disease in cell-free cerebrospinal fluid. Mol. Neurobiol. 53, 2894–9 (2016).

    Article  PubMed  Google Scholar 

  73. 73.

    Denk, J. et al. MicroRNA profiling of CSF reveals potential biomarkers to detect Alzheimer’s disease. PLoS One 10, e0126423 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  74. 74.

    van Harten, A. C., Mulders, J., Scheltens, P., van der Flier, W. M. & Oudejans, C. B. Differential expression of microRNA in cerebrospinal fluid as a potential novel biomarker for Alzheimer’s disease. J. Alzheimers Dis. 47, 243–52 (2015).

    Article  PubMed  Google Scholar 

  75. 75.

    Blore, J. D., Sim, M. R., Forbes, A. B., Creamer, M. C. & Kelsall, H. L. Depression in Gulf War veterans: a systematic review and meta-analysis. Psychol. Med. 45, 1565–1580 (2015).

    CAS  Article  PubMed  Google Scholar 

  76. 76.

    Stimpson, N. J., Thomas, H. V., Weightman, A. L., Dunstan, F. & Lewis, G. Psychiatric disorder in veterans of the Persian Gulf War of 1991. Systematic review. Br. J. Psychiatry. 182, 391–403 (2003).

    Article  PubMed  Google Scholar 

  77. 77.

    Valero, S. et al. The role of neuroticism, perfectionism and depression in chronic fatigue syndrome. A structural equation modeling approach. Compr. Psychiatry. 54, 1061–7 (2013).

    Article  PubMed  Google Scholar 

  78. 78.

    Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. (American Psychiatric Association, Washington, DC, 1994).

  79. 79.

    McKenzie, D. P. et al. Developing a brief depression screen and identifying associations with comorbid physical and psychological illness in Australian Gulf War veterans. J. Psychosom. Res. 79, 566–73 (2015).

    Article  PubMed  Google Scholar 

  80. 80.

    Shafer, A. B. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. J. Clin. Psychol. 62, 123–46 (2006).

    Article  PubMed  Google Scholar 

  81. 81.

    Clarke, D. M. & McKenzie, D. P. A caution on the use of cut-points applied to screening instruments or diagnostic criteria. J. Psychiatr. Res. 28, 185–8 (1994).

    CAS  Article  PubMed  Google Scholar 

  82. 82.

    Nanthakumar, S., Bucks, R. S. & Skinner, T. C. Are we overestimating the prevalence of depression in chronic illness using questionnaires? Meta-analytic evidence in obstructive sleep apnoea. Health Psychol. 35, 423–32 (2016).

    Article  PubMed  Google Scholar 

  83. 83.

    Pincus, T., Hassett, A. L. & Callahan, L. F. Criterion contamination of depression scales in patients with rheumatoid arthritis: the need for interpretation of patient questionnaires (as all clinical measures) in the context of all information about the patient. Rheum. Dis. Clin. North. Am. 35, 861–4 (2009).

    Article  PubMed  Google Scholar 

  84. 84.

    Dwivedi, Y. Pathogenetic and therapeutic applications of microRNAs in major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry. 64, 341–8 (2016).

    CAS  Article  Google Scholar 

  85. 85.

    Song, M. F. et al. CSF miR-16 is decreased in major depression patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter system. J. Affect. Disord. 178, 25–31 (2015).

    CAS  Article  PubMed  Google Scholar 

  86. 86.

    Wan, Y. et al. Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PLoS One. 10, e0121975 (2015).

    Article  PubMed  PubMed Central  Google Scholar 

  87. 87.

    Bjersing, J. L. et al. Profile of cerebrospinal microRNAs in fibromyalgia. PLoS One 8, e78762 (2013).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  88. 88.

    McAlexander, M. A., Phillips, M. J. & Witwer, K. W. Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid. Front. Genet. 4, 83 (2013).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  89. 89.

    Andersen., C. L., Jensen, J. L. & Ørntoft, T. F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64, 5245–50 (2004).

    CAS  Article  PubMed  Google Scholar 

  90. 90.

    Burgos, K. et al. Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology. PLoS One. 9, e94839 (2014).

    ADS  Article  PubMed  PubMed Central  Google Scholar 

  91. 91.

    Nassirpour, R. et al. Identification of tubular injury microRNA biomarkers in urine: comparison of next-generation sequencing and qPCR-based profiling platforms. BMC Genomics 15, 485 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  92. 92.

    Kuner, R., Brase, J. C., Sültmann, H. & Wuttig, D. microRNA biomarkers in body fluids of prostate cancer patients. Methods 59, 132–7 (2013).

    CAS  Article  PubMed  Google Scholar 

  93. 93.

    Baraniuk, J. N. & Shivapurkar, N. Cerebrospinal fluid MicroRNA (miRNA) in CFS and Gulf War Illness (GWI). International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (IACFSME). Fort Lauderdale FLA, Oct. 2016.

  94. 94.

    Brenu, E. W. et al. High-throughput sequencing of plasma microRNA in chronic fatigue syndrome/myalgic encephalomyelitis. PLoS One. 9, e102783 (2014).

    ADS  Article  PubMed  PubMed Central  Google Scholar 

  95. 95.

    Lopez, J. P. et al. MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nat. Commun. 8, 15497 (2017).

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references


The study was supported by funding from The Sergeant Sullivan Circle, Dr. Barbara Cottone, Dean Clarke Bridge Prize, Department of Defense Congressionally Directed Medical Research Program (CDMRP) W81XWH-15-1-0679, and National Institute of Neurological Diseases and Stroke R21NS088138 and RO1NS085131.

Author information




J.N.B. organized the studies. N.S. performed the QPCR in blinded fashion. J.N.B. and N.S. wrote the paper.

Corresponding author

Correspondence to James N. Baraniuk.

Ethics declarations

Competing Interests

The authors declare that they have no competing interests.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Baraniuk, J.N., Shivapurkar, N. Exercise – induced changes in cerebrospinal fluid miRNAs in Gulf War Illness, Chronic Fatigue Syndrome and sedentary control subjects. Sci Rep 7, 15338 (2017).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing